The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and CRISPR Therapeutics wasn’t one of them. The 10 stocks that made the ...
Take CRISPR Therapeutics (NASDAQ: CRSP) and Intellia Therapeutics (NASDAQ: NTLA), two biotechs specializing in gene editing. Finance, is $83.60; the latter earns a price target of $50.80 from ...
Biotech companies can skyrocket in a short period because of excellent clinical or regulatory progress. And if we take the ...
CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report)’s share price was down 4.7% during mid-day trading on Monday after an insider sold shares in the company. The stock traded as low as $45.16 and ...
CRISPR Therapeutics CRSP stock rose more than 25% in the past week, thanks to the encouraging fourth-quarter 2024 results and a rating upgrade by a Wall Street analyst. Alongside earnings results ...
Insider Monkey on MSN8d
CRISPR Therapeutics AG (CRSP): Among the Most Oversold Healthcare Stocks to Buy NowWe recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a ...
In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against the other oversold pharma stocks to buy according to analysts. On February 20, Emily Field ...
CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has received a consensus rating of “Moderate Buy” from the twenty-two ...
A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the ...
StockNews.com upgraded shares of CRISPR Therapeutics (NASDAQ:CRSP – Free Report) to a sell rating in a research report ...
Take CRISPR Therapeutics (NASDAQ: CRSP) and Intellia Therapeutics (NASDAQ: NTLA), two biotechs specializing in gene editing. Finance, is $83.60; the latter earns a price target of $50.80 from ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results